Neuroelectrics

Neuroelectrics operates across medical devices, neuroscience, diagnostics, and digital brain health, with products serving both research and clinical applications. Its portfolio spans Enobio wireless EEG, Starstim electrical-stimulation systems, the NIC Software Suite, and remotely supervised home-based research through Starstim-Home. This combination of monitoring, stimulation, software, and remote study management differentiates its offering from a portfolio limited to EEG recording or standalone stimulation hardware. The company also describes capabilities for combining stimulation with EEG and fNIRS, supporting multimodal research and closed-loop approaches. Its competitive context is best understood as the overlap between neurotechnology device makers, clinical EEG providers, and brain-stimulation developers. Its key distinction is an integrated hardware-and-software ecosystem with remote research capabilities.

Founded in 2012, Neuroelectrics has built a product portfolio around wireless EEG, transcranial electrical stimulation, research software, and remote study support. Its funding history records a 2016 non-equity assistance round with no disclosed amount, followed by a $17.5 million Series A led by Morningside on May 4, 2021. That financing is the clearest capital inflection point in the available history; no later funding round or valuation is listed. The company’s product range includes the Enobio EEG system, Starstim systems, Starstim-Home, NIC Software Suite, and Neurotwin Digital Brain Twin. The December 2024 Neuronostics partnership marks a further step toward integrating its EEG capabilities into clinical-trial services, while the 2024 depression telemedicine pilot highlights remote-care research. The recorded employee range is 11–50, but no hiring trend or recent team expansion is specified. Overall, the trajectory reflects gradual development from neurotechnology research hardware toward a broader platform spanning devices, software, and clinical applications, with limited evidence about commercial scale or growth after 2024.